BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, Wirtz H, Koschel D, Andreas S, Claussen M, Grohé C, Wilkens H, Hagmeyer L, Skowasch D, Meyer JF, Kirschner J, Gläser S, Kahn N, Welte T, Neurohr C, Schwaiblmair M, Held M, Bahmer T, Oqueka T, Frankenberger M, Behr J. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respir Res 2019;20:59. [PMID: 30876420 DOI: 10.1186/s12931-019-1020-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 11.7] [Reference Citation Analysis]
Number Citing Articles
1 Wuyts WA, Dahlqvist C, Slabbynck H, Schlesser M, Gusbin N, Compere C, Maddens S, Rizzo S, Kirchgaessler K, Bartley K, Bondue B. Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry. Pulm Ther. [DOI: 10.1007/s41030-022-00187-8] [Reference Citation Analysis]
2 Kreuter M, Picker N, Schwarzkopf L, Baumann S, Cerani A, Postema R, Maywald U, Dittmar A, Langley J, Patel H. Epidemiology, healthcare utilization, and related costs among patients with IPF: results from a German claims database analysis. Respir Res 2022;23. [DOI: 10.1186/s12931-022-01976-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kreuter M, Del Galdo F, Miede C, Khanna D, Wuyts WA, Hummers LK, Alves M, Schoof N, Stock C, Allanore Y. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis. Arthritis Res Ther 2022;24:19. [PMID: 35012623 DOI: 10.1186/s13075-021-02710-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hilberg O, Hoffmann-vold A, Smith V, Bouros D, Kilpeläinen M, Guiot J, Morais A, Clemente S, Daniil Z, Papakosta D, Fretheim H, Neves S, Alfaro TM, Antoniou KM, Valveny N, Asijee G, Soulard S, Wuyts W. Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries. ERJ Open Res 2022;8:00597-2021. [DOI: 10.1183/23120541.00597-2021] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Aronson KI, Suzuki A. Health Related Quality of Life in Interstitial Lung Disease: Can We Use the Same Concepts Around the World? Front Med (Lausanne) 2021;8:745908. [PMID: 34692737 DOI: 10.3389/fmed.2021.745908] [Reference Citation Analysis]
6 Prior TS, Hoyer N, Shaker SB, Davidsen JR, Hilberg O, Patel H, Bendstrup E. Validation of a derived version of the IPF-specific Saint George's Respiratory Questionnaire. Respir Res 2021;22:259. [PMID: 34610840 DOI: 10.1186/s12931-021-01853-2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Lancaster L, Bonella F, Inoue Y, Cottin V, Siddall J, Small M, Langley J. Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. Respirology 2021. [PMID: 34611971 DOI: 10.1111/resp.14154] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Kirsten D, de Vries U, Costabel U, Koschel D, Bonella F, Günther A, Behr J, Claussen M, Schwarz S, Prasse A, Kreuter M. A New Tool to Assess Quality of Life in Patients with Idiopathic Pulmonary Fibrosis or Non-specific Interstitial Pneumonia. Pneumologie 2021. [PMID: 34521147 DOI: 10.1055/a-1579-7618] [Reference Citation Analysis]
9 Nambiar AM, Walker CM, Sparks JA. Monitoring and management of fibrosing interstitial lung diseases: a narrative review for practicing clinicians. Ther Adv Respir Dis 2021;15:17534666211039771. [PMID: 34477452 DOI: 10.1177/17534666211039771] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
10 Kirsten D, de Vries U, Costabel U, Koschel D, Bonella F, Günther A, Behr J, Claussen M, Schwarz S, Prasse A, Kreuter M. [Linguistic Validation of the "German Lung Fibrosis Health Related Quality of Life Questionnaire"]. Pneumologie 2021;75:753-60. [PMID: 34428830 DOI: 10.1055/a-1334-2745] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Aronson KI, Danoff SK, Russell AM, Ryerson CJ, Suzuki A, Wijsenbeek MS, Bajwah S, Bianchi P, Corte TJ, Lee JS, Lindell KO, Maher T, Martinez FJ, Meek PM, Raghu G, Rouland G, Rudell R, Safford MM, Sheth JS, Swigris JJ. Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med 2021;204:e3-e23. [PMID: 34283696 DOI: 10.1164/rccm.202105-1193ST] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
12 Maher TM, Bendstrup E, Dron L, Langley J, Smith G, Khalid JM, Patel H, Kreuter M. Global incidence and prevalence of idiopathic pulmonary fibrosis. Respir Res 2021;22:197. [PMID: 34233665 DOI: 10.1186/s12931-021-01791-z] [Cited by in F6Publishing: 27] [Reference Citation Analysis]
13 Prior TS, Hoyer N, Hilberg O, Shaker SB, Davidsen JR, Rasmussen F, Bendstrup E. Clusters of comorbidities in idiopathic pulmonary fibrosis. Respir Med 2021;185:106490. [PMID: 34130097 DOI: 10.1016/j.rmed.2021.106490] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
14 Case AH, Hellkamp AS, Neely ML, Bender S, Dilling DF, Gulati M, Hotchkin DL, Huie TJ, Lancaster L, Snyder LD, Conoscenti CS, Palmer SM. Associations between Patient-reported Outcomes and Death or Lung Transplant in Idiopathic Pulmonary Fibrosis. Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry. Ann Am Thorac Soc 2020;17:699-705. [PMID: 32040340 DOI: 10.1513/AnnalsATS.201906-437OC] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
15 Poletti V, Vancheri C, Albera C, Harari S, Pesci A, Metella RR, Campolo B, Crespi G, Rizzoli S; FIBRONET study group. Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study. Respir Res 2021;22:66. [PMID: 33627105 DOI: 10.1186/s12931-021-01643-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
16 Spencer LG, Loughenbury M, Chaudhuri N, Spiteri M, Parfrey H. Idiopathic pulmonary fibrosis in the UK: analysis of the British Thoracic Society electronic registry between 2013 and 2019. ERJ Open Res 2021;7:00187-2020. [PMID: 33532476 DOI: 10.1183/23120541.00187-2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
17 Crespo A, Alfaro T, Somogyi V, Kreuter M. Updates in using a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples. Breathe (Sheff) 2020;16:200067. [PMID: 33447271 DOI: 10.1183/20734735.0067-2020] [Reference Citation Analysis]
18 Mori Y, Kondoh Y. What parameters can be used to identify early idiopathic pulmonary fibrosis? Respir Investig 2021;59:53-65. [PMID: 33277230 DOI: 10.1016/j.resinv.2020.10.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Liu Y, Wang Y, Lu F, Wang L, Miao L, Wang X. BTB and CNC homology 1 inhibition ameliorates fibrosis and inflammation via blocking ERK pathway in pulmonary fibrosis. Exp Lung Res 2021;47:67-77. [PMID: 33238752 DOI: 10.1080/01902148.2020.1849448] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Leuschner G, Klotsche J, Kreuter M, Prasse A, Wirtz H, Pittrow D, Frankenberger M, Behr J, Kneidinger N; INSIGHTS-IPF Registry Group. Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study. Front Med (Lausanne) 2020;7:601279. [PMID: 33313046 DOI: 10.3389/fmed.2020.601279] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
21 Cox IA, Borchers Arriagada N, de Graaff B, Corte TJ, Glaspole I, Lartey S, Walters EH, Palmer AJ. Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Eur Respir Rev 2020;29:200154. [PMID: 33153990 DOI: 10.1183/16000617.0154-2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
22 Maqhuzu PN, Szentes BL, Kreuter M, Bahmer T, Kahn N, Claussen M, Holle R, Schwarzkopf L. Determinants of health-related quality of life decline in interstitial lung disease. Health Qual Life Outcomes 2020;18:334. [PMID: 33032602 DOI: 10.1186/s12955-020-01570-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
23 Lasky JA, Criner GJ, Lazarus HM, Kohlbrenner V, Bender S, Richeldi L. Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data. Adv Ther 2020;37:4209-19. [PMID: 32767182 DOI: 10.1007/s12325-020-01452-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
24 Fenwick KE, Swan BA. Managing Dyspnea in Individuals With Idiopathic Pulmonary Fibrosis. J Hosp Palliat Nurs 2020;22:447-55. [PMID: 32956191 DOI: 10.1097/NJH.0000000000000687] [Reference Citation Analysis]
25 George PM, Spagnolo P, Kreuter M, Altinisik G, Bonifazi M, Martinez FJ, Molyneaux PL, Renzoni EA, Richeldi L, Tomassetti S, Valenzuela C, Vancheri C, Varone F, Cottin V, Costabel U. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. The Lancet Respiratory Medicine 2020;8:925-34. [DOI: 10.1016/s2213-2600(20)30355-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 94] [Article Influence: 20.5] [Reference Citation Analysis]
26 Yuan XY, Zhang H, Huang LR, Zhang F, Sheng XW, Cui A. Evaluation of health-related quality of life and the related factors in a group of Chinese patients with interstitial lung diseases. PLoS One 2020;15:e0236346. [PMID: 32726327 DOI: 10.1371/journal.pone.0236346] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
27 Jarosch I, Schneeberger T, Gloeckl R, Kreuter M, Frankenberger M, Neurohr C, Prasse A, Freise J, Behr J, Hitzl W, Koczulla AR, Kenn K. Short-Term Effects of Comprehensive Pulmonary Rehabilitation and its Maintenance in Patients with Idiopathic Pulmonary Fibrosis: A Randomized Controlled Trial. J Clin Med 2020;9:E1567. [PMID: 32455843 DOI: 10.3390/jcm9051567] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
28 Shi H, Yin D, Bonella F, Kreuter M, Oltmanns U, Li X, Peng S, Wei L. Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis. BMC Pulm Med 2020;20:128. [PMID: 32380989 DOI: 10.1186/s12890-020-1121-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
29 Prior TS, Hoyer N, Hilberg O, Shaker SB, Davidsen JR, Bendstrup E. Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis. Respir Res 2020;21:91. [PMID: 32316976 DOI: 10.1186/s12931-020-01359-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
30 George PM, Wells AU. Contemporary Concise Review 2019: Interstitial lung disease. Respirology 2020;25:756-63. [PMID: 32187808 DOI: 10.1111/resp.13803] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Culver DA, Behr J, Belperio JA, Corte TJ, de Andrade JA, Flaherty KR, Gulati M, Huie TJ, Lancaster LH, Roman J, Ryerson CJ, Kim HJ. Patient Registries in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2019;200:160-7. [PMID: 31034241 DOI: 10.1164/rccm.201902-0431CI] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 13.5] [Reference Citation Analysis]
32 Tzouvelekis A, Karampitsakos T, Kourtidou S, Bouros E, Tzilas V, Katsaras M, Antonou C, Dassiou M, Bouros D. Impact of Depression on Patients With Idiopathic Pulmonary Fibrosis. Front Med (Lausanne) 2020;7:29. [PMID: 32118014 DOI: 10.3389/fmed.2020.00029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
33 Kreuter M, Wuyts WA, Wijsenbeek M, Bajwah S, Maher TM, Stowasser S, Male N, Stansen W, Schoof N, Orsatti L, Swigris J. Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials. Respir Res 2020;21:36. [PMID: 32000772 DOI: 10.1186/s12931-020-1298-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
34 Richeldi L, Kolb M, Jouneau S, Wuyts WA, Schinzel B, Stowasser S, Quaresma M, Raghu G. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med 2020;20:3. [PMID: 31914963 DOI: 10.1186/s12890-019-1030-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 25] [Article Influence: 8.5] [Reference Citation Analysis]
35 Janssen K, Rosielle D, Wang Q, Kim HJ. The impact of palliative care on quality of life, anxiety, and depression in idiopathic pulmonary fibrosis: a randomized controlled pilot study. Respir Res 2020;21:2. [PMID: 31900187 DOI: 10.1186/s12931-019-1266-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
36 Yu XQ, Yang SG, Xie Y, Li JS. Traditional Chinese medicine in the treatment of idiopathic pulmonary fibrosis based on syndrome differentiation: Study protocol of an exploratory trial. J Integr Med 2020;18:163-8. [PMID: 31928920 DOI: 10.1016/j.joim.2019.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
37 Moor CC, Wijsenbeek MS, Balestro E, Biondini D, Bondue B, Cottin V, Flewett R, Galvin L, Jones S, Molina-Molina M, Planas-Cerezales L, Prasse A, Prosch H, Russell AM, Viegas M, Wanke G, Wuyts W, Kreuter M, Bonella F. Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey. ERJ Open Res 2019;5:00124-2019. [PMID: 31649949 DOI: 10.1183/23120541.00124-2019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
38 Somogyi V, Chaudhuri N, Torrisi SE, Kahn N, Müller V, Kreuter M. The therapy of idiopathic pulmonary fibrosis: what is next? Eur Respir Rev 2019;28:190021. [PMID: 31484664 DOI: 10.1183/16000617.0021-2019] [Cited by in Crossref: 50] [Cited by in F6Publishing: 66] [Article Influence: 16.7] [Reference Citation Analysis]